Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Insmed (NASDAQ:INSM), a clinical-stage biotechnology company focused on inhaled therapies for diseases of the lung, jumped as much as 18% after a pair of brokerage firms boosted their price targets on the company.
So what: Just hours apart from one another, Canaccord Genuity boosted its price target on Insmed from $12 to $17 while Leerink Swann raised its target all the way to $22 from $13. The impetus behind both price target hikes was similar: an expected approval of Arikace, the company's inhaled first-line treatment for non-tuberculosis mycobacterial infections. These two price target bumps come one week after Lazard Capital Management raised its price target on Insmed to $21 and the covering analyst, Joshua Schimmer, projecting sales of $600 million annually by 2020.
Now what: While certainly a good day for existing shareholders, let's remember that analyst actions should be taken with a grain of salt as they rarely have any long-term bearing on a stocks' share price or your investing thesis. The reality here is that Insmed still doesn't have a drug approved by the Food and Drug Administration, it's burning cash, and it could be at least two more years before it gets Arikace in front of the European Medicines Agency for an approval decision. A U.S. decision will be yet another year or two beyond that. With a cash burn rate that I anticipate will be right around $50 million annually, it won't be long before Insmed needs cash again and reaches to potentially dilutive offerings to accomplish this. I'd strongly suggest keeping your distance.
Craving more input? Start by adding Insmed to your free and personalized watchlist so you can keep up on the latest news with the company.